ES2532516A1 - Método de diagnóstico y pronóstico de melanoma cutáneo - Google Patents

Método de diagnóstico y pronóstico de melanoma cutáneo Download PDF

Info

Publication number
ES2532516A1
ES2532516A1 ES201331404A ES201331404A ES2532516A1 ES 2532516 A1 ES2532516 A1 ES 2532516A1 ES 201331404 A ES201331404 A ES 201331404A ES 201331404 A ES201331404 A ES 201331404A ES 2532516 A1 ES2532516 A1 ES 2532516A1
Authority
ES
Spain
Prior art keywords
skin cancer
melanoma skin
prognosis
diagnosis
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201331404A
Other languages
English (en)
Other versions
ES2532516B1 (es
Inventor
María Dolores BOYANO LÓPEZ
Yoana ARROLLO BERDUGO
Santos ALONSO ALEGRE
Aintzane ASUMENDI MALLEA
Gorka PÉREZ-YARZA PÉREZ-IREZÁBAL
Jesús María CAREAGA ALZAGA
Jesús GARDEAZÁBAL GARCÍA
Rosa IZU BELLOSO
Jose Luis DÍAZ RAMÓN
Elvira ACEBO MARIÑAS
Ana SÁNCHEZ DÍEZ
Íñigo MARTÍNEZ DE LIZARDUY
Juan Antonio RATÓN NIETO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euskal Herriko Unibertsitatea
Administracion General de la Comunidad Autonoma de Euskadi
Original Assignee
Euskal Herriko Unibertsitatea
Administracion General de la Comunidad Autonoma de Euskadi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euskal Herriko Unibertsitatea, Administracion General de la Comunidad Autonoma de Euskadi filed Critical Euskal Herriko Unibertsitatea
Priority to ES201331404A priority Critical patent/ES2532516B1/es
Priority to EP14796149.4A priority patent/EP3051291B1/en
Priority to PCT/ES2014/070737 priority patent/WO2015044499A1/es
Priority to ES14796149T priority patent/ES2732854T3/es
Publication of ES2532516A1 publication Critical patent/ES2532516A1/es
Application granted granted Critical
Publication of ES2532516B1 publication Critical patent/ES2532516B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

La presente invención se refiere a un método in vitro para diagnosticar melanoma cutáneo y un método in vitro para diferenciar nevus benigno de melanoma en una lesión cutánea basados en determinar el nivel de expresión de un marcador seleccionado del grupo formado por BCL3, PIR, PEBP1 y sus combinaciones. Adicionalmente, la invención se refiere a un método in vitro para determinar la probabilidad de metástasis en un sujeto diagnosticado con melanoma cutáneo basado en determinar el nivel de expresión de un marcador seleccionado del grupo formado por M-MITF, PIR, BCL2 y sus combinaciones.

Description

imagen1

Claims (1)

  1. imagen1
ES201331404A 2013-09-26 2013-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo Withdrawn - After Issue ES2532516B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201331404A ES2532516B1 (es) 2013-09-26 2013-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo
EP14796149.4A EP3051291B1 (en) 2013-09-26 2014-09-26 Method for the diagnosis and prognosis of skin melanoma
PCT/ES2014/070737 WO2015044499A1 (es) 2013-09-26 2014-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo
ES14796149T ES2732854T3 (es) 2013-09-26 2014-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201331404A ES2532516B1 (es) 2013-09-26 2013-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo

Publications (2)

Publication Number Publication Date
ES2532516A1 true ES2532516A1 (es) 2015-03-27
ES2532516B1 ES2532516B1 (es) 2016-01-15

Family

ID=51871086

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201331404A Withdrawn - After Issue ES2532516B1 (es) 2013-09-26 2013-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo
ES14796149T Active ES2732854T3 (es) 2013-09-26 2014-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14796149T Active ES2732854T3 (es) 2013-09-26 2014-09-26 Método de diagnóstico y pronóstico de melanoma cutáneo

Country Status (3)

Country Link
EP (1) EP3051291B1 (es)
ES (2) ES2532516B1 (es)
WO (1) WO2015044499A1 (es)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARDILE, V., MALAPONTE, G., LORETO, C. et al. Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas. Acta histochemica (17-04-2013). Vol 115, Páginas 795-802. *
LICCIULLI, S.,LUISE, C., SCAFETTA, G et al. Pirin Inhibits Cellular Senescence in Melanocytic Cells. The american Journal of Pathology (05- 2011). Vol 178, páginas 2397-2406. *
PALMIERI, G., CAPONE, M., ASCIERTO, M. L. ET AL. Main roads to melanoma. Journal of translational medicine, (14-10-2009), Vol 7, Nº1 , páginas 1-17. *
WENDLER, W., KREMMER, E., F?RSTER, R. et al. Identification of pirin, a novel highly conserved nuclear protein. Journal of Biological Chemistry (1997). Vol 272, paginas 8482-8489. *
ZHUANG,L.,LEE, C.S., SCOLYER, R.A et al. Mcl-1, Bcl-XL and Stat3 expression areassociated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology (2007) Vol 20, p?ginas 416-426. *
ZHUANG,L.,LEE, C.S., SCOLYER, R.A et al. Mcl-1, Bcl-XL and Stat3 expression areassociated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology (2007) Vol 20, paginas 416-426. *

Also Published As

Publication number Publication date
EP3051291A1 (en) 2016-08-03
EP3051291B1 (en) 2019-01-30
ES2732854T3 (es) 2019-11-26
ES2532516B1 (es) 2016-01-15
WO2015044499A1 (es) 2015-04-02

Similar Documents

Publication Publication Date Title
MX2019005748A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CY1119689T1 (el) Μεθοδοι και συνθεσεις για την ανιχνευση του επιπεδου της δραστικοτητας της λυσοσωμικης εξωκυτταρωσης και μεθοδοι χρησης
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
MX2020010147A (es) Metodos para predecir el riesgo de neumonia intersticial.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2019006005A (es) Metodos para la deteccion de cancer.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2022002138A (es) Estandares de antigeno prostatico y sus usos.
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2018010536A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
IN2013CH05587A (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2532516

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160115

FA2A Application withdrawn

Effective date: 20160629